Open-label study to assess safety and efficacy of a single dose (i.v.) of NMK36 in subjects with prostate cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221289

Enrollment

Registered

2010-11-01

Start date

2010-11-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

investigational material(s) Generic name etc : fluciclovine(18F) INN of investigational material : fluciclovine(18F) Therapeutic category code : 43- Radioactive medicines Dosage and Administration for

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: -The subject has biopsy-proven prostate cancer. -The subject has lymph node and/or bone metastasis from prostate cancer detected by CT, MRI or bone scintigraphy.

Exclusion criteria

Exclusion criteria: -The subject received treatment for prostate cancer. -The subject has a dysfunction of bone-marrow, hepatic or renal.

Design outcomes

Primary

Measure	Time frame
safety Safety: subjective/objective symptoms, electrocardiogram exam, vital signs,clinical test efficacy Efficacy: imaging charactaristics of primary and metastatic prostate cancer, range of administratored radioactivity, starting time for PET imaging	—

Secondary

Measure	Time frame
other None	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026